Association between the CHEK2*1100delC germ line mutation and estrogen receptor status

Int J Gynecol Cancer. 2006:16 Suppl 2:552-5. doi: 10.1111/j.1525-1438.2006.00694.x.

Abstract

Already published data were further analyzed regarding the association between the CHEK2*1100delC germ line mutation and estrogen receptor (ER) status in patients with breast cancer. The CHEK2*1100delC mutation was more prevalent among the patients with a positive ER status (4.2% versus 1.0%). An ER-negative status was beside CHEK2*1100delC mutation and independently associated with an earlier of age onset of breast cancer. There was a trend that an ER-negative status, beside the presence of a CHEK2*1100delC mutation, was associated with a worse disease-free survival. There might be an association between ER status and a CHEK2*1100delC mutation. More studies with larger number of patients are needed to further investigate the relation between CHEK2*1100delC and ER status.

Publication types

  • Comparative Study
  • Multicenter Study

MeSH terms

  • Breast Neoplasms / genetics*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Case-Control Studies
  • Checkpoint Kinase 2
  • Female
  • Genes, BRCA1
  • Genes, BRCA2
  • Genetic Predisposition to Disease
  • Genotype
  • Germ-Line Mutation / genetics*
  • Humans
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Protein Serine-Threonine Kinases / genetics*
  • Receptors, Estrogen / metabolism*
  • Survival Rate

Substances

  • Receptors, Estrogen
  • Checkpoint Kinase 2
  • CHEK2 protein, human
  • Protein Serine-Threonine Kinases